| Mr Kashif Aslam, MD | |
|
3301 Matlock Rd, Arlington, TX 76015-2908 | |
| (682) 509-6200 | |
| Not Available |
| Full Name | Mr Kashif Aslam |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 24 Years |
| Location | 3301 Matlock Rd, Arlington, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548432636 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 264794 (Massachusetts) | Secondary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | S4719 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Mansfield Medical Center | Mansfield, TX | Hospital |
| Medical City Arlington | Arlington, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pulmonary Critical Care Professionals | 2062884471 | 6 |
| Questcare Pulmonary In-patient Services Pllc | 0244577385 | 15 |
News Archive
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
A lethal, but long-overlooked cancer will take a major step out of the shadows next week, as The Mesothelioma Applied Research Foundation convenes the First International Symposium on Malignant Mesothelioma.
According to the latest available research, should a global influenza pandemic become a reality, small stockpiles of a secondary flu medication, provided they are used early enough in local outbreaks, could extend the effectiveness of large primary stockpiles of drugs such as Tamiflu.
Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.
› Verified 3 days ago
| Entity Name | Questcare Pulmonary In-patient Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629553375 PECOS PAC ID: 0244577385 Enrollment ID: O20190128000476 |
News Archive
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
A lethal, but long-overlooked cancer will take a major step out of the shadows next week, as The Mesothelioma Applied Research Foundation convenes the First International Symposium on Malignant Mesothelioma.
According to the latest available research, should a global influenza pandemic become a reality, small stockpiles of a secondary flu medication, provided they are used early enough in local outbreaks, could extend the effectiveness of large primary stockpiles of drugs such as Tamiflu.
Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.
› Verified 3 days ago
| Entity Name | White Rock Pulmonary, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376289983 PECOS PAC ID: 3274900287 Enrollment ID: O20221104000094 |
News Archive
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
A lethal, but long-overlooked cancer will take a major step out of the shadows next week, as The Mesothelioma Applied Research Foundation convenes the First International Symposium on Malignant Mesothelioma.
According to the latest available research, should a global influenza pandemic become a reality, small stockpiles of a secondary flu medication, provided they are used early enough in local outbreaks, could extend the effectiveness of large primary stockpiles of drugs such as Tamiflu.
Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.
› Verified 3 days ago
| Entity Name | Pulmonary Critical Care Professionals |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922714179 PECOS PAC ID: 2062884471 Enrollment ID: O20230214000034 |
News Archive
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
A lethal, but long-overlooked cancer will take a major step out of the shadows next week, as The Mesothelioma Applied Research Foundation convenes the First International Symposium on Malignant Mesothelioma.
According to the latest available research, should a global influenza pandemic become a reality, small stockpiles of a secondary flu medication, provided they are used early enough in local outbreaks, could extend the effectiveness of large primary stockpiles of drugs such as Tamiflu.
Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.
› Verified 3 days ago
| Entity Name | Vital Hospital Partners Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922786649 PECOS PAC ID: 4789045949 Enrollment ID: O20230803003003 |
News Archive
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
A lethal, but long-overlooked cancer will take a major step out of the shadows next week, as The Mesothelioma Applied Research Foundation convenes the First International Symposium on Malignant Mesothelioma.
According to the latest available research, should a global influenza pandemic become a reality, small stockpiles of a secondary flu medication, provided they are used early enough in local outbreaks, could extend the effectiveness of large primary stockpiles of drugs such as Tamiflu.
Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.
› Verified 3 days ago
| Entity Name | Dfw Lung Health Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407548969 PECOS PAC ID: 3173981651 Enrollment ID: O20230911002694 |
News Archive
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
A lethal, but long-overlooked cancer will take a major step out of the shadows next week, as The Mesothelioma Applied Research Foundation convenes the First International Symposium on Malignant Mesothelioma.
According to the latest available research, should a global influenza pandemic become a reality, small stockpiles of a secondary flu medication, provided they are used early enough in local outbreaks, could extend the effectiveness of large primary stockpiles of drugs such as Tamiflu.
Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Kashif Aslam, MD 7814 Uxbridge Drive, Irving, TX 75063-1001 Ph: (347) 452-0967 | Mr Kashif Aslam, MD 3301 Matlock Rd, Arlington, TX 76015-2908 Ph: (682) 509-6200 |
News Archive
Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.
A lethal, but long-overlooked cancer will take a major step out of the shadows next week, as The Mesothelioma Applied Research Foundation convenes the First International Symposium on Malignant Mesothelioma.
According to the latest available research, should a global influenza pandemic become a reality, small stockpiles of a secondary flu medication, provided they are used early enough in local outbreaks, could extend the effectiveness of large primary stockpiles of drugs such as Tamiflu.
Enobia Pharma Inc., today announced that it has successfully completed enrollment in its Phase II study of ENB-0040, a bone targeted enzyme replacement therapy being investigated in adolescents and adults with hypophosphatasia, a serious, rare metabolic bone disorder.
› Verified 3 days ago
Dr. Waldo P Bracy Jr., M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 N Waldrop Dr, Ste. 509, Arlington, TX 76012 Phone: 817-394-4300 Fax: 817-394-0200 | |
Thang D Le, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 W Randol Mill Rd Ste 2300, Arlington, TX 76012 Phone: 866-202-1032 Fax: 817-548-6649 | |
Dr. Hujefa Yusuf Vora, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 3150 Matlock Rd, Suite 403, Arlington, TX 76015 Phone: 817-784-0052 Fax: 817-375-5800 | |
Dr. Raza Askari, Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 515 W Mayfield Rd Ste 210, Arlington, TX 76014 Phone: 817-375-5847 | |
Thuc Quyen Thi Nguyen, Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 515 W Mayfield Rd, Suite 210, Arlington, TX 76014 Phone: 817-417-4027 Fax: 817-417-4043 | |
Dr. Bienvenido Gatmaitan Gatmaitan, Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 621 Matlock Centre Cir, Arlington, TX 76015 Phone: 817-860-6062 Fax: 817-795-6652 | |
Bernard A Mcgowen, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 1217 Florida Dr, Suite 121, Arlington, TX 76015 Phone: 817-419-9155 Fax: 817-419-9412 |